1. Pink Sheet
  2. >>Market Access

Access To Innovation Looking Brighter In France

 
• By Ian Schofield and Ayisha Sharma

French Biotech In Focus: The French biotech industry body France Biotech says that the authorities are making good progress in reducing the time taken to get new medicines on the market, but that low drug prices and high industry taxes remain key challenges for the industry.

France Biotech Focus
France Is Allowing Biotech Companies To Make Their Products Available Earlier • Source: Shutterstock

Two key initiatives taken by the French government over the past couple of years are helping to improve patients’ access to innovative drugs, says the biotech industry’s representative body, France Biotech.

These are a reform of the temporary use authorization (ATU) process, and the ability for new products to be launched as soon as the health technology appraisal (HTA) has been carried out

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

Recent and Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 
• By Anabel Costa-Ferreira

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 
• By Eliza Slawther

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.